Role of Inflammasome Activation in Lung Injury Highlighted at Neonatal Research Symposium

December 19, 2023

Rashmin C. Savani, MBChB, Head of Scientific Advisory Board, Azome Therapeutics, spoke on the critical role of RHAMM ((Receptor for Hyaluronan-Mediated Motility) in inflammasome activation at the 15th Annual Bowman Symposium on Neonatal Research held on November 8-9 at The Children’s Hospital Research Institute of Manitoba in Winnipeg, Canada.

Dr. Savani’s talk, ““The Pathophysiology of Lung Injury and Inflammation,” discussed the mechanisms controlling inflammation and the role of inflammasome activation in disease processes. During the symposium, he also participated in a Cardiorespiratory Research “Meet the Experts” panel hosted by the Biology of Breathing Research Trainees’ Hub.

Azome Therapeutics is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including acute lung injury, Acute Respiratory Distress Syndrome, Bronchopulmonary Dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia.  The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks a key upstream priming signal involved in the aberrant activation of the NLRP3 inflammatory cascade.

Azome Data Presented at ASMB Biennial Meeting

November 20, 2023

Azome Therapeutics’ groundbreaking peptide technology that blocks inflammasome activation was the subject of a talk given by Rashmin C. Savani, MBChB, Head of Scientific Advisory Board at the Biennial Meeting of the American Society for Matrix Biology held in Salt Lake City, October 22–25.

In his presentation, “Towards the Universality of TLR Signaling: Developing Novel Therapeutics,” Dr. Savani provided an overview of the research supporting the company’s RHAMM (Receptor for Hyaluronan-Mediated Motility) antagonist technology platform.

Azome Therapeutics is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including acute lung injury, Acute Respiratory Distress Syndrome, Bronchopulmonary Dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia. The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks a key upstream priming signal involved in the aberrant activation of the NLRP3 inflammatory cascade.

Azome data presented at 12th International Proteoglycans Conference

September 25, 2023

Rashmin Savani, MBChB, Head of Scientific Advisory Board, Azome Therapeutics,

spoke on the critical role of RHAMM in inflammasome activation at the 89th Harden Conference and 12th International Proteoglycans Conference held September 4-7 in Surrey, England.  

Dr. Savani’s presentation reviewed multiple infectious and non-infectious models where RHAMM (Receptor for Hyaluronan-Mediated Motility) plays a critical role in the inflammatory process leading to disease and included highlights from the company’s preclinical research.  During the conference, Dr. Savani also chaired the “Translational Advances” session.